Servier buys into MacroGenics' Phase I anticancer MAb
This article was originally published in Scrip
Executive Summary
Servier is to pay an initial $20 million to Rockville, Maryland-based privately held biotech firm MacroGenics to access the latter's MGA271, an Fc-optimised therapeutic monoclonal antibody that targets the immune regulator B7-H3 and is in Phase I trials to treat solid tumours.
You may also be interested in...
MacroGenics Signs Another Lucrative DART Deal with Janssen For $75m Up Front
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.